2021 Should be An Informative Year - Cure Parkinson's

Cure Parkinson's

25,341 members26,642 posts

2021 Should be An Informative Year

jimcaster profile image
34 Replies

Parkinson’s disease research has ended in numerous dead ends despite substantial efforts over many years. Recently, Biogen and Sanofi scrapped their Parkinson’s candidates, cipanemab and venglustat respectively, owing to lack of efficacy, and a disease-modifying therapy has yet to materialise.

But the push to find drugs that help beyond reducing symptoms continues, and Evaluate Vantage has delved into the pipeline of projects in active late-stage clinical trials. This year is shaping up to be crucial for the field, with 10 studies expected to yield data or to complete in 2021.

One target that crops up multiple times is GLP-1; this approach, traditionally employed in type 2 diabetes, is also being tested in Alzheimer’s. Among other avenues of research, it is hoped that gene therapy could offer a one-time cure for Parkinson’s.

evaluate.com/vantage/articl...

Written by
jimcaster profile image
jimcaster
To view profiles and participate in discussions please or .
Read more about...
34 Replies

4 of the 19 trials are Exenatide. There is a lot of hope and money invested in Exanatide.

pdpatient profile image
pdpatient in reply to

@cclemonade, sorry to cast some Coldwater on your enthusiasm and hope for a second time today 🤨

I have been on Exenatide since 2006 and I personally don't think it would have made a difference. I got Parkinson's anyways and it didn't do much to help with my symptoms which is tremor dominant.

RKM

in reply to pdpatient

I did not say I have a lot of hope and money in Exenatide. I said there IS a lot of hope and money in Exenatide. Big destinction.

WinnieThePoo profile image
WinnieThePoo in reply to

It's a disease modifier not a symptom reliever. It might be that with exanatide it takes 20 years to progress to stage 3 instead of the 10. I'd take that as a good start.

pdpatient profile image
pdpatient in reply to WinnieThePoo

@winniethepoo, you perhaps do have a point. My diagnosis symptoms have not progressed over nearly 10 years and come to think of it, it is certainly possible.

RKM

in reply to pdpatient

Your symptoms have not progressed for nearly 10 years and you are on Exenatide. I doubt that is a coincidence. I’m perplexed then by your stating that it didn’t do much to help.

WinnieThePoo profile image
WinnieThePoo in reply to pdpatient

Exanatide is being trialed as a disease modifier. Something which slows the rate at which your parkinson's progresses. Why would you expect it to do anything for your existing symptoms?

pdpatient profile image
pdpatient in reply to WinnieThePoo

@winniethepoo. Your point well taken. Never viewed my plight / fortune with this perspective. However, your position speculates that disease modification and symptoms are synonymous with each other and one is indicative of the other. At least that is the way, I have seen most research being presented or perceived.

RKM

WinnieThePoo profile image
WinnieThePoo in reply to pdpatient

I think the way trials like the exanatide one (or my SPARK trial) measure disease progression is to look at symptoms over time, and compare the rate at which symptoms progress (off meds)

Initially it is hard to be sure whether the symptomatic result is due to the drug relieving the symptom or the drug "putting out the fire" that causes the symptoms to get worse.

There are 2 ways of trying to isolate the disease modifying / progression slowing effect from simple symptomatic relief

"Wash out" - after (say) 12 months drug use, stop drug use at month 12 and observe the symptom at month 12 and (say) month 15. If the benefit remains at month 15 it is likely it is due to the disease slowing properties rather than simple symptomatic relief. If you stopped Sinemet on month 12 and assessed symptoms at month 15 - they would be much worse

The 2nd method is to review at multiple points. If you measure the symptom at month 12 and month 24 and the result remains constant, then it is likely to be a progression slowing effect. Especially when you consider the measurement is off-meds (No sinemet, pramipexole etc for 24 hours before the assessment)

in reply to WinnieThePoo

Well said. Thank you.

bassofspades profile image
bassofspades

Genomic therapy in 5...4...3....2.....

in reply to bassofspades

Bass of Spades, your upbeat attitude is wonderful and very healthy! Along the path to genomic therapy I foresee a disease slowing treatment of some sort and stem cells and FUS.

bassofspades profile image
bassofspades in reply to

The thing with stem cells is that it doesn't stop the disease process, so those replaced cells might feel good for a while but they eventually die back from the same things as the old ones.

Gene therapy will target the specific defects, in protein synthesis for example. New methods in gene mapping will allow us to see exactly where things are going wrong and target the specific areas of the genome. Cancers will be cured like you've never imagined, too! They're already having success with things like sickle cell anemia and beta thalassemia, which are rare blood disorders. Just trust me , it's totally do-able and it's coming!

kevowpd profile image
kevowpd in reply to bassofspades

Will this gene therapy help those that have already lost <70% of their dopamine transporters?

bassofspades profile image
bassofspades in reply to kevowpd

I hope so ! That's all of us!

kevowpd profile image
kevowpd in reply to bassofspades

Conceptually, I'm not sure why fixing up my genes will help with the damage already done. But i have to confess to knowing absolutely nothing about it.

As for the theories about transplanting new cells into a hostile environment, I'm not convinced that its futile. The death of dopamine transporters is actually fairly slow. If we say you start with 1m DTs, and wr accept the 10 year / 70% estimates, then you lose 7% or 70,000 every year. If you can load up on another 500,000, then that might buy you another 500,000/70,000=7 years.

in reply to kevowpd

A study done in Lund Sweden in the 80’s, proved that the implanted neurons lived and were effective for over 20 years. I am new to understanding the trial process.

Is it reasonable to think that if a stem cell trial is said to take 7 years that in reality it could be 15+ years bc multiple rounds of trials might be necessary? Of course I hope they hit it out of the park in the first go but that seems rather unlikely.

in reply to bassofspades

I understand. But to my knowledge stem cells are farther along and therefore have a greater likelihood of being accessible to us someday. That was my only point. Hopefully I’m wrong. Are there in human trials for gene therapy for PD?

bassofspades profile image
bassofspades in reply to

I dont know of any specific PD trials. All I know is that the supporting technology of that field is growing at an EXPONENTIAL RATE.

PixelPaul profile image
PixelPaul in reply to

Assuming that stem cells are proven to be an effective treatment, the problem I see with them is one of scale. It is a highly invasive surgical procedure, and given its current state I don’t see how that realistically scales to the masses.

in reply to PixelPaul

The same can be said of DBS yet it is a viable option for many.

PalmSprings profile image
PalmSprings in reply to bassofspades

Does gene therapy have potential for those of us with non genetically linked Parkinson’s?

bassofspades profile image
bassofspades in reply to PalmSprings

youtu.be/PkukxG6UDvc

The answer is within the first 3 minutes

PalmSprings profile image
PalmSprings in reply to bassofspades

Thanks, that was super informative and interesting!

Gioc profile image
Gioc in reply to PalmSprings

Hi PalmSprings,

There are various ways to use this discovery, here is a recent one ... and "promising" ... about mice.

nature.com/articles/s41586-...

Here is a more understandable explanation, maybe:

healthdesk.it/ricerca/terap...

PalmSprings profile image
PalmSprings in reply to Gioc

Thanks, so interesting!

bassofspades profile image
bassofspades in reply to Gioc

Yes!!

MBAnderson profile image
MBAnderson

Thnx. Good info.

in reply to MBAnderson

Hey! What are you doing on here?! Are you in Switzerland?

MBAnderson profile image
MBAnderson in reply to

I am. Having my head examined.

AmyLindy profile image
AmyLindy in reply to MBAnderson

Safe Travels 🇺🇸 🇨🇭 🇺🇸

MBAnderson profile image
MBAnderson in reply to

"What am I doing on here?" I am in quarantine with nothing else to do, so you're stuck with me.

in reply to MBAnderson

😁 I’m so glad you are in good spirits Hey, the dog is cute but I miss the baby.

Canddy profile image
Canddy

thank You! Very informative!

You may also like...

Matt Eagles: Positivity in Adversity – 46 years living with Parkinson’s

topic of “Positivity in Adversity – 46 years living with Parkinson’s“. Diagnosed with Parkinson's...

Interview of Daphne Bryan following the publication of her book: “Parkinson’s and the B1 therapy”.

progression in the disease over the five years he worked with them. Daphne Bryan outlines the...

Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? 2021

it, things will pop out. Tidbits. Clues. Parkinson’s Disease: Can Targeting Inflammation Be an...

Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease 2021

until the end of therapy. Moreover, no adverse event was recorded. After 1 week of therapy...

Twist of fate: What happens when a top Parkinson's researcher gets the disease?

physician-scientist has probed Parkinson’s disease for more than 30 years. Now, he has it...